Two additional caveats: Phillip Frost holds ~ 20% of the shares. Phase II is really only a pilot study since (in addition to what you've mentioned) it was also short treatment (one month), patients weren't hGH-naïve, and primary endpoint was IGF-1 levels, these are not the conditions for the future phase III trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.